🔷 Approval is supported by positive Phase III ARANOTE data, enabling physicians to better tailor treatment plans for men with mHSPC.

🔗 Read more: bit.ly/ONCOnews04Fe...

#ONCOnews #OncoAlert #OncEd #Nubeqa #Darolutamide #ProstateCancer #mHSPC #ClinicalTrials

Bayer's prostate cancer drug Nubeqa cleared for NHS use Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

#menshealth #NICErecommended #Bayer #prostatecancer #Nubeqa #darolutamide #Nubeqaregimen #hormonesensitiveprostatecancer #HSPC #androgendeprivationtherapy #ProstateCancerUK #advancedHSPC #ARANOTEtrial #castrationresistantprostatecancer #CRPC #mHSPC #NationalProstateCancerAudit #NPCA
zurl.co/dDIIm

Bayer scores UK NICE nod for Nubeqa in prostate cancer NICE approves Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) for treating men with hormone-sensitive metastatic prostate cancer.

News for prostate cancer patients in England and Wales — NICE has recommended Bayer’s Nubeqa plus ADT as a new NHS treatment option for men with hormone-sensitive metastatic prostate cancer.

#News #ProstateCancer #NICE #Bayer #Nubeqa #Darolutamide #CancerResearch #MensHealth #Oncology #NHS

Bayer scores UK NICE nod for Nubeqa in prostate cancer NICE approves Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) for treating men with hormone-sensitive metastatic prostate cancer.

News for prostate cancer patients in England and Wales — NICE has recommended Bayer’s Nubeqa plus ADT as a new NHS treatment option for men with hormone-sensitive metastatic prostate cancer.

#News #ProstateCancer #NICE #Bayer #Nubeqa #Darolutamide #CancerResearch #MensHealth #Oncology #NHS

Darolutamide (Nubeqa) 2025 Updates: A Patient Guide to Treatment for Prostate Cancer - OncoDaily Learn more about Darolutamide (Nubeqa), its uses in cancer, dosage, side effects, expectation.

Darolutamide (Nubeqa) 2025 Updates: A Patient Guide to Treatment for Prostate Cancer

oncodaily.com/drugs/darolu...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Darolutamide #Nubeqa #ProstateCancer

Darolutamide (Nubeqa) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily darolutamide (nubeqa) is approved to treat of nmCRPC and mHSPC. Learn about its uses, side effects, dosage and expectations.

Darolutamide (Nubeqa) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/darolu...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Darolutamide #Nubeqa #ProstateCancer #CSPC

Cancro prostata avanzato, Ema raccomanda terza indicazione per darolutamide (Adnkronos) - Il Comitato per i medicinali per uso umano (Chmp) dell’Agenzia europea per i medicinali (Ema) ha raccomandato darolutamide, inibitore orale del recettore degli androgeni (Ari), più terapia di deprivazione androgenica (A...

Cancro prostata avanzato, Ema raccomanda terza indicazione per darolutamide ... LEGGI TUTTO #CancroProstata #Darolutamide #Ema #TerapiaDeprivazioneAndrogenica #Salute

The Phase III ARANOTE trial reveals promising results for darolutamide + ADT in metastatic hormone-sensitive prostate cancer (#mHSPC)! 🎗️

🔬 Key Findings 👇

@ascocancer.bsky.social

#Onco404 #Cancer #Oncology #ProstateCancer #ClinicalTrials #Darolutamide #Healthcare #JCO #medsky #oncsky

New insights from the UCBG 3-06 START trial, a multicentre, randomized phase 2 study, evaluating the anti-androgen darolutamide in AR-positive TNBC

@thelancetoncol.bsky.social

#Onco404 #Cancer #Oncology #BreastCancer #oncsky #medsky #ClinicalTrials #TNBC #AndrogenReceptor #Darolutamide

New Research:

#Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced #breastcancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial

#TNBC

RedHill Biopharma Begins Phase 2 Trial for New Prostate Cancer Treatment RedHill Biopharma has initiated a placebo-controlled Phase 2 study examining the combination of opaganib and darolutamide for advanced prostate cancer treatment, supported by Bayer.

RedHill Biopharma Begins Phase 2 Trial for New Prostate Cancer Treatment #Israel #Tel_Aviv #RedHill_Biopharma #Opaganib #darolutamide

ASCO Publications

Terapia con darolutamida y terapia de deprivación androgénica es eficaz y tolerable en pacientes con cáncer de próstata metastásico sensible a hormona, mejorando la supervivencia libre de progresión radiológica y la seguridad #darolutamide #ADT #mHSPC ascopubs.org/doi/full/10....

NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC - OncoDaily NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC / cancer, darolutamide, docetaxel, Metastatic Hormone-sensitive Prostate Cancer,

NCODA’s PQI simplifies the use of Darolutamide with Docetaxel for mHSPC

oncodaily.com/insight/201195

#Cancer #Darolutamide #Docetaxel #ProstateCancer #MetastaticProstateCancer #mHSPC #NCODA #NCODAPQI #OncoDaily #Oncology #PQIinAction